Cardiac function surveillance practices and outcomes in patients with HER2-positive breast cancer treated with trastuzumab: a retrospective cohort study across a safety-net and tertiary care setting
Abstract Background Anti-HER2 receptor monoclonal antibodies like trastuzumab are the mainstay of treatment in HER2-positive breast cancer but can result in cancer therapy-related cardiac dysfunction (CTRCD). Guidelines recommend cardiac surveillance prior to anti-HER2 therapy initiation, every 3 mo...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Cardio-Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40959-025-00376-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|